Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Optinose transferred with an Outperform at RBC Capital » 16:56
04/06/21
04/06
16:56
04/06/21
16:56
OPTN

Optinose

$3.57 /

+0.01 (+0.28%)

RBC Capital transferred…

RBC Capital transferred coverage of Optinose to analyst Daniel Busby, also keeping an Outperform rating and $17 price target on the stock.

ShowHide Related Items >><<
OPTN Optinose
$3.57 /

+0.01 (+0.28%)

OPTN Optinose
$3.57 /

+0.01 (+0.28%)

06/30/20 Cantor Fitzgerald
OptiNose anti-COVID-19 candidate could provide 'significant upside, says Cantor
OPTN Optinose
$3.57 /

+0.01 (+0.28%)

  • 14
    Aug
OPTN Optinose
$3.57 /

+0.01 (+0.28%)

Over a month ago
Options
Two new option listings and two option delistings on March 18th » 08:30
03/18/21
03/18
08:30
03/18/21
08:30
OPTN

Optinose

$3.86 /

-0.06 (-1.53%)

, SRTS

Sensus Healthcare

$4.39 /

-0.02 (-0.45%)

, QEP

QEP Resources

$4.10 /

+ (+0.00%)

, RLH

Red Lion Hotels

$3.49 /

-0.01 (-0.29%)

New option listings for…

New option listings for March 18th include OptiNose Inc (OPTN) and Sensus Healthcare (SRTS). Option delistings effective March 18th include Qep Resources Inc (QEP) and Red Lion Hotels (RLH).

ShowHide Related Items >><<
SRTS Sensus Healthcare
$4.39 /

-0.02 (-0.45%)

RLH Red Lion Hotels
$3.49 /

-0.01 (-0.29%)

QEP QEP Resources
$4.10 /

+ (+0.00%)

OPTN Optinose
$3.86 /

-0.06 (-1.53%)

OPTN Optinose
$3.86 /

-0.06 (-1.53%)

06/30/20 Cantor Fitzgerald
OptiNose anti-COVID-19 candidate could provide 'significant upside, says Cantor
SRTS Sensus Healthcare
$4.39 /

-0.02 (-0.45%)

03/01/21 H.C. Wainwright
Sensus Healthcare price target raised to $6 from $4 at H.C. Wainwright
02/26/21 Northland
Northland upgrades Sensus Healthcare to Outperform after 'strong' Q4 report
02/26/21 Northland
Sensus Healthcare upgraded to Outperform from Market Perform at Northland
12/16/20 Northland
Sensus Healthcare downgraded to Market Perform on valuation at Northland
QEP QEP Resources
$4.10 /

+ (+0.00%)

01/25/21 Stifel
QEP Resources downgraded to Hold from Buy at Stifel
12/28/20 Northland
Diamondback Energy price target raised to $60 from $50 at Northland
12/22/20 Stephens
Diamondback Energy price target raised to $67 from $56 at Stephens
12/22/20 Susquehanna
Diamondback Energy deal strengthens free cash flow, says Susquehanna
RLH Red Lion Hotels
$3.49 /

-0.01 (-0.29%)

01/04/21 Craig-Hallum
Red Lion Hotels downgraded to Hold at Craig-Hallum
01/04/21 Craig-Hallum
Red Lion Hotels downgraded to Hold from Buy at Craig-Hallum
06/04/20 Craig-Hallum
Red Lion Hotels upgraded to Buy from Hold at Craig-Hallum
SRTS Sensus Healthcare
$4.39 /

-0.02 (-0.45%)

RLH Red Lion Hotels
$3.49 /

-0.01 (-0.29%)

QEP QEP Resources
$4.10 /

+ (+0.00%)

OPTN Optinose
$3.86 /

-0.06 (-1.53%)

  • 14
    Aug
QEP QEP Resources
$4.10 /

+ (+0.00%)

RLH Red Lion Hotels
$3.49 /

-0.01 (-0.29%)

Hot Stocks
Optinose expects topline results from OPN-019 study in 2Q21 » 07:06
03/03/21
03/03
07:06
03/03/21
07:06
OPTN

Optinose

$3.92 /

-0.085 (-2.12%)

In June 2020, the Company…

In June 2020, the Company announced the initiation of development of a new product candidate, OPN-019, which combines its proprietary intranasal Exhalation Delivery System with an antiseptic. Because components of the drug-device combination product candidate, including both the active drug and delivery device, are currently commercially available in the U.S., the Company anticipates a potential streamlined and accelerated development. Subsequent to a pre-Investigational New Drug submission the Company is engaged with FDA regarding an IND and clinical development pathway. The Company has performed in vitro testing against SARS-CoV-2 with a candidate formulation in which a 4-log reduction in virus count was produced. In addition, the Company performed tests against other pathogens. For most pathogens tested, 3-log to 6-log reductions in virus count were observed. In April 2021, the Company expects to initiate a randomized, proof of concept study in subjects who have tested positive for SARS-CoV-2 infection, are recently infected, and who have mild or no symptoms. This pilot study being conducted in Mexico will evaluate both the magnitude and duration of viral load reduction after a single dose of OPN-019. The Company expects top-line results from this study in second quarter 2021. The Company is focused on supporting the initial stages of development within our current operating expense guidance and intend to seek grants, partnerships, and/or other sources of capital to fund future development.

ShowHide Related Items >><<
OPTN Optinose
$3.92 /

-0.085 (-2.12%)

OPTN Optinose
$3.92 /

-0.085 (-2.12%)

06/30/20 Cantor Fitzgerald
OptiNose anti-COVID-19 candidate could provide 'significant upside, says Cantor
OPTN Optinose
$3.92 /

-0.085 (-2.12%)

  • 14
    Aug
Hot Stocks
Optinose expects topline results from one XHANCE trial by end of 2021 » 07:05
03/03/21
03/03
07:05
03/03/21
07:05
OPTN

Optinose

$3.92 /

-0.085 (-2.12%)

The Company expects…

The Company expects top-line results from one of its clinical trials evaluating XHANCE as a potential treatment for Chronic Sinusitis by the end of 2021 and the other in the first half of 2022. Pauses in patient enrollment, due to the COVID-19 pandemic, at some clinical trial sites changed the Company's prior expectation of top-line results from both trials in the second half of 2021.

ShowHide Related Items >><<
OPTN Optinose
$3.92 /

-0.085 (-2.12%)

OPTN Optinose
$3.92 /

-0.085 (-2.12%)

06/30/20 Cantor Fitzgerald
OptiNose anti-COVID-19 candidate could provide 'significant upside, says Cantor
OPTN Optinose
$3.92 /

-0.085 (-2.12%)

  • 14
    Aug
Earnings
Optinose expects Q1 XHANCE revenues to decrease vs. Q4 » 07:05
03/03/21
03/03
07:05
03/03/21
07:05
OPTN

Optinose

$3.92 /

-0.085 (-2.12%)

Revenue consensus…

Revenue consensus $18.65M.

ShowHide Related Items >><<
OPTN Optinose
$3.92 /

-0.085 (-2.12%)

OPTN Optinose
$3.92 /

-0.085 (-2.12%)

06/30/20 Cantor Fitzgerald
OptiNose anti-COVID-19 candidate could provide 'significant upside, says Cantor
OPTN Optinose
$3.92 /

-0.085 (-2.12%)

  • 14
    Aug
Hot Stocks
Optinose sees FY21 XHANCE revenues at least $80M » 07:04
03/03/21
03/03
07:04
03/03/21
07:04
OPTN

Optinose

$3.92 /

-0.085 (-2.12%)

Revenue consensus…

Revenue consensus $103.19M. The Company expects XHANCE net revenues for the full year of 2021 to be at least $80 million. This includes the Company's expectation that first quarter 2021 XHANCE net revenue will decrease compared to fourth quarter 2020. The primary driver of the sequential decrease to revenue is the Company's expectation that XHANCE average net revenue per prescription for the first quarter of 2021 will be between $120 and $140, due to typical early-year effects on price and volume related to patient insurance that the Company believes are common for chronic treatments that derive a significant proportion of total prescriptions from refills. The Company expects XHANCE average net revenue per prescription to improve substantially for the remainder of 2021. In addition, the Company expects full year 2021 XHANCE net revenue per prescription to increase compared to full year 2020 XHANCE net revenue per prescription of $185. The Company expects total GAAP operating expenses for 2021 to be in the range of $137 - $142 million, of which the Company expects stock-based compensation to be approximately $11 million.

ShowHide Related Items >><<
OPTN Optinose
$3.92 /

-0.085 (-2.12%)

OPTN Optinose
$3.92 /

-0.085 (-2.12%)

06/30/20 Cantor Fitzgerald
OptiNose anti-COVID-19 candidate could provide 'significant upside, says Cantor
OPTN Optinose
$3.92 /

-0.085 (-2.12%)

  • 14
    Aug
Earnings
Optinose reports Q4 EPS (46c), consensus (46c) » 07:02
03/03/21
03/03
07:02
03/03/21
07:02
OPTN

Optinose

$3.92 /

-0.085 (-2.12%)

Reports Q4 revenue…

Reports Q4 revenue $16.3M, consensus $17.93M. "I am proud of how the team at Optinose responded to the market disruptions created by the global pandemic, enabling us to deliver 70% year-over-year growth of prescriptions for XHANCE," stated CEO Peter Miller. "As a launch-stage product, new patient starts are a critical driver of future success. Following pandemic-related disruption in second quarter, we achieved consecutive all-time highs for new prescriptions of XHANCE in third and fourth quarter 2020. Looking ahead, we believe we expect sustained or increased XHANCE growth in 2021. Our expectations for first quarter 2021 include typical early-year effects on price and volume related to patient insurance that we believe are common for chronic treatments that derive a significant proportion of total prescriptions from refills, and for full year 2021 we expect XHANCE net revenue to be at least $80 million."

ShowHide Related Items >><<
OPTN Optinose
$3.92 /

-0.085 (-2.12%)

OPTN Optinose
$3.92 /

-0.085 (-2.12%)

06/30/20 Cantor Fitzgerald
OptiNose anti-COVID-19 candidate could provide 'significant upside, says Cantor
OPTN Optinose
$3.92 /

-0.085 (-2.12%)

  • 14
    Aug
Over a quarter ago
Hot Stocks
Optinose expects topline results from XHANCE trials in 2H21 » 07:32
11/05/20
11/05
07:32
11/05/20
07:32
OPTN

Optinose

$3.54 /

-0.215 (-5.73%)

The Company expects total…

The Company expects total GAAP operating expenses for 2020 to be in the range of $127 - $132 million, of which the Company expects stock-based compensation to be approximately $10 million. Previously the Company expected total GAAP operating expenses for 2020 to be in the range of $131 - $136 million, of which stock-based compensation was expected to be approximately $11 million. The Company expects top-line results from both of its clinical trials evaluating XHANCE as a potential treatment for Chronic Sinusitis in the second half of 2021. The Company expects to draw $20 million of cash from its debt facility by early 2021, subject to continuing to meet eligibility requirements.

ShowHide Related Items >><<
OPTN Optinose
$3.54 /

-0.215 (-5.73%)

OPTN Optinose
$3.54 /

-0.215 (-5.73%)

06/30/20 Cantor Fitzgerald
OptiNose anti-COVID-19 candidate could provide 'significant upside, says Cantor
02/07/20 Piper Sandler
Piper Sandler views Optinose risk/reward as attractive after allergist survery
12/18/19 Cowen
Optinose initiated with an Outperform at Cowen
OPTN Optinose
$3.54 /

-0.215 (-5.73%)

  • 14
    Aug
  • 21
    Nov
OPTN Optinose
$3.54 /

-0.215 (-5.73%)

Earnings
Optinose reports Q3 EPS (43c), consensus (52c) » 07:31
11/05/20
11/05
07:31
11/05/20
07:31
OPTN

Optinose

$3.54 /

-0.215 (-5.73%)

Reports Q3 revenue…

Reports Q3 revenue $15.4M, consensus $14.28M. "New and total prescriptions for XHANCE reached an all-time quarterly high in the third quarter of 2020. We are pleased with this achievement after experiencing a challenging environment in the second quarter 2020 due to significant pandemic-related declines in patient volume in ENT and Allergy offices," stated CEO Peter Miller. "As a result of increased demand and improvement in net revenue per prescription, XHANCE net revenues were $15.4 million. By exceeding the third quarter 2020 net revenue threshold specified in our debt facility, we open up the option to draw an additional $20 million to add to our cash position, which would extend our cash runway and further enable us to focus on growth. Finally, we are excited by recent events that we believe meaningfully support XHANCE growth potential as we progress into 2021. These include both our co-promotion with kaleo, which first hit the field in October and grows our sales reach and frequency, and the new publication by Brent Senior, M.D., Professor of Otolaryngology and Vice Chair of Academics and Outreach at the University of North Carolina, and others that describes the value of XHANCE in the population of patients who are still symptomatic on conventional nasal steroids."

ShowHide Related Items >><<
OPTN Optinose
$3.54 /

-0.215 (-5.73%)

OPTN Optinose
$3.54 /

-0.215 (-5.73%)

06/30/20 Cantor Fitzgerald
OptiNose anti-COVID-19 candidate could provide 'significant upside, says Cantor
02/07/20 Piper Sandler
Piper Sandler views Optinose risk/reward as attractive after allergist survery
12/18/19 Cowen
Optinose initiated with an Outperform at Cowen
OPTN Optinose
$3.54 /

-0.215 (-5.73%)

  • 14
    Aug
  • 21
    Nov
OPTN Optinose
$3.54 /

-0.215 (-5.73%)

Earnings
Optinose sees Q3 XHANCE net product revenues $15.4M » 07:02
10/22/20
10/22
07:02
10/22/20
07:02
OPTN

Optinose

$3.61 /

-0.2 (-5.25%)

Revenue consensus…

Revenue consensus $13.88M. Optinose announced preliminary XHANCE net product revenues of $15.4M for the three months ended September 30, 2020. XHANCE net product revenues increased 78% compared to the three months ended September 30, 2019, and 50% compared to the three months ended June 30, 2020. This financial information is preliminary and subject to change. The Company expects to report full financial results for the third quarter of 2020 and corporate updates before market open on Thursday, November 5, 2020.

ShowHide Related Items >><<
OPTN Optinose
$3.61 /

-0.2 (-5.25%)

OPTN Optinose
$3.61 /

-0.2 (-5.25%)

06/30/20 Cantor Fitzgerald
OptiNose anti-COVID-19 candidate could provide 'significant upside, says Cantor
02/07/20 Piper Sandler
Piper Sandler views Optinose risk/reward as attractive after allergist survery
12/18/19 Cowen
Optinose initiated with an Outperform at Cowen
OPTN Optinose
$3.61 /

-0.2 (-5.25%)

  • 14
    Aug
  • 21
    Nov
OPTN Optinose
$3.61 /

-0.2 (-5.25%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.